The Global Resource for Advancing Cancer Education (GRACE), presents Molecular Diagnostic Testing and Next Generation Sequencing in Lung Cancer webinar series.
, , , ,
Dr. Alice Shaw joined GRACE to discuss patterns of resistance in ALK positive non small cell lung cancer.
Lung Cancer Video Library 2017 - New Options in Acquired Resistance for ALK Positive Non-small Cell Lung Cancer (NSCLC)
Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses new options in acquired resistance for ALK positive non-small cell lung cancer (NSCLC).
Download the speaker presentations and handouts from the Targeted Therapies Patient Forum in Cleveland at the Taussig Cancer Center on September 16, 2017.
On Saturday, September 16, 2017, patients, caregivers, family members and friends joined GRACE in Cleveland at the Taussig Cancer Center for a full...
- 1 of 13
- View More
Christine M. Walko, Pharm.D., discusses how advancements in technology have improved the quality, cost and turnaround time for assessing genetic mutations in tumor tissue, and how this has helped to translate precision medicine into standard clinical practice.
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.
Brendan Bietry of the Patient Advocate Foundation discusses the financial assistance programs available to lung cancer patients who receive targeted therapies.
Dr. West moderates a question & answer session with Drs. Leora Horn and Greg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
Repeat Biopsies and Emerging Technologies for Plasma Sampling of Mutations Seen with Acquired Resistance
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.
- 1 of 62
- View More
Progression after 3 1/2 years on Tarceva. Tissue biopsy showed T790m negative. Any suggestions/experience on next steps? Onc suggesting I move to Afatinib or a Opdivo. PDL1 was tested and is <1%.